ReviewWorld journal of gastroenterology2014
Melatonin for the treatment of irritable bowel syndrome.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- The value of melatonin supplementation in postmenopausal women with Helicobacter pylori-associated dyspepsia.BMC women's health · 2020Trial
- The Effects of Melatonin on Elevated Liver Enzymes during Statin Treatment.BioMed research international · 2017Trial
- Agomelatine improves symptom severity and quality of life in diarrhea-predominant irritable bowel syndrome: insights from a randomized controlled clinical trial.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Sleep and Disorders of Gut-Brain Interaction.Gastroenterology & hepatology · 2026Article
- Therapeutic Use of Melatonin for Gastrointestinal Motility and Hypersomnolence in a Patient With Pineal Cyst Pathology.The American journal of case reports · 2026Article
- Melatonin alleviates diarrhea and visceral hypersensitivity in rats with diarrhea-predominant irritable bowel syndrome by modulating of the TLR4/MyD88/NF-κB pathway.BMC gastroenterology · 2025Article
- IBS May Have a Causal Effect on Increased Tryptophan Metabolites Levels: Insights from a Bidirectional Two-Sample Mendelian Randomization Study.International journal of tryptophan research : IJTR · 2025Article
- Mind-Body Interventions for Comorbid Sleep and Gastrointestinal Concerns.Current sleep medicine reports · 2025Review
- Article
- Looking for a Beam of Light to Heal Chronic Pain.Journal of pain research · 2024Review
- Therapeutic targets and potential delivery systems of melatonin in osteoarthritis.Frontiers in immunology · 2024Review
- Melatonin Alleviates Intestinal Barrier Damaging Effects Induced by Polyethylene Microplastics in Albino Rats.International journal of molecular sciences · 2023Article
- Dietary effects of melatonin on growth performance by modulation of protein bioavailability and behavior in early weaned rats and pigs.Journal of animal science and technology · 2023Article
- Article
- Is Melatonin the "Next Vitamin D"?: A Review of Emerging Science, Clinical Uses, Safety, and Dietary Supplements.Nutrients · 2022Review
- Protective Effects of Melatonin and Misoprostol against Experimentally Induced Increases in Intestinal Permeability in Rats.International journal of molecular sciences · 2022Article
- Progress on the Mechanism of Visceral Hypersensitivity in Nonerosive Reflux Disease.Gastroenterology research and practice · 2022Review
- Article
- Chemotherapeutics-Induced Intestinal Mucositis: Pathophysiology and Potential Treatment Strategies.Frontiers in pharmacology · 2021Review
- Sleep disorders related to nutrition and digestive diseases: a neglected clinical condition.International journal of medical sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain or discomfort, in combination with disturbed bowel habits in the absence of identifiable organic cause. Melatonin (N-acetyl-5-methoxytryptamine) is a hormone produced by the pineal gland and also large number by enterochromaffin cells of the digestive mucosa. Melatonin plays an important part in gastrointestinal physiology which includes regulation of gastrointestinal motility, local anti-inflammatory reaction as well as moderation of visceral sensation. Melatonin is commonly given orally. It is categorized by the United States Food and Drug Administration as a dietary supplement. Melatonin treatment has an extremely wide margin of safety though it may cause minor adverse effects, such as headache, rash and nightmares. Melatonin was touted as a potential effective candidate for IBS treatment. Putative role of melatonin in IBS treatment include analgesic effects, regulator of gastrointestinal motility and sensation to sleep promoter. Placebo-controlled studies in melatonin suffered from heterogeneity in methodology. Most studies utilized 3 mg at bedtime as the standard dose of trial. However, all studies had consistently showed improvement in abdominal pain, some showed improvement in quality of life of IBS patients. Melatonin is a relatively safe drug that possesses potential in treating IBS. Future studies should focus on melatonin effect on gut mobility as well as its central nervous system effect to elucidate its role in IBS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.